STAT Plus: GSK took a leap of faith on PARP inhibitors in cancer. It may pay off
AKIRA SUEMORI/AP
The company has argued that that there are diseases beyond breast and ovarian cancer in which the drug Zejula would work in a larger group of patients.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario